Latest "Placebo Hepatitis Virus Infection" News Stories

04:33 EDT 26th October 2014 | BioPortfolio

Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.

More Information about Placebo Hepatitis Virus Infection on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.

Showing "Placebo Hepatitis Virus Infection" News Articles 1–25 of 9,500+

Extremely Relevant

[Comment] Hepatitis virus and HIV interactions

Because of shared routes of transmission, 5–25% of the 34 million people with HIV worldwide are co-infected with either hepatitis B virus (HBV), hepatitis C virus (HCV), or both, with the highest number of co-infections in low-income countries. The...

[Seminar] Hepatitis B virus infection

Hepatitis B virus infection is a major public health problem worldwide; roughly 30% of the world's population show serological evidence of current or past infection. Hepatitis B virus is a partly double-stranded DNA virus with several serological mar...

[Articles] HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010–12: a retrospective observational cohort study

Screening for viral hepatitis is important in individuals diagnosed as HIV positive. Effective management for viral hepatitis should be integrated into HIV treatment programmes. Long-term data are needed about the effect of hepatitis co-infection on ...

Hepatitis C Cases Could Be Cured By Novel Oral Drug Regimen

According to the results of two new clinical studies published in The Lancet, two new pill-only antiviral drug regimens for hepatitis C virus infection provide shorter and more effective treatment options with fewer side effects for most patients af...

Hepatitis C Infection May Have 'Silver Lining' for Transplant Patients

WEDNESDAY, June 25, 2014 -- The liver-damaging hepatitis C virus may come with an unexpected benefit for patients who need a liver transplant due to the infection, a new European study reports. The virus appears to restrain a dangerous immune...

Should Direct-Acting Antiviral Agents Replace the Standard of Care for Hepatitis C Infection?

Lansdale, PA (PRWEB) September 15, 2014 For the 3.2 million people in the United States infected with the hepatitis C virus, disease management can be costly and debilitating. But are the new agents recently approved by the Food and Drug Administr...

Quantum Leaps, Microeconomics, and the Treatment of Patients With Hepatitis C and HIV Coinfection

Until very recently, patients with hepatitis C virus (HCV) infection were treated with pegylated-interferon administered weekly by subcutaneous injection plus ribavirin given orally twice daily. Over the last decade, however, by virtue of development...

Researchers discover how Hepatitis C virus persists for years

Hepatitis C virus (HCV) lingers in the human body for years, slowly damaging the liver and leading to liver diseases such as hepatitis, cirrhosis and liver cancer, which is often fatal. Research conducted at the University of North Carolina at Chapel...

Ciclofilin developing first drug for HCV/HIV-1 co-infection

Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity directed against both viruses. “Other companies are working on one or the other virus, so we would like to position ourselves as the company working on co-infection, where our […]

Medical News Today: Study identifies global prevalence of hepatitis C virus genotypes

Researchers from the UK have identified the worldwide prevalence of hepatitis C virus genotypes, in the hope it will help develop new treatment strategies for the infection.

Transmission of hepatitis C virus following antiviral treatment

Millions of people throughout the world are infected with hepatitis C virus (HCV). Left untreated, infection results in serious complications such as cirrhosis of the liver and cancer. Many HCV-infected patients respond well to anti-viral therapy and...

CDC Celebrates 25th Anniversary of the Discovery of the Hepatitis C Virus

Twenty-five years ago the Centers for Disease Control and Prevention (CDC) played a pivotal role in the discovery of the virus that causes hepatitis C. After the isolation of HCV, implementation of screening of blood products and organs for donation led to a decrease in rates of HCV infection between 1990 and 2009. In spite of these successes, HCV

Task Force Recommends Screening High-Risk Individuals for Hepatitis B Infection

Individuals who are at high risk of infection with the hepatitis B virus (HBV) should be screened, according to a new recommendation from the US Preventive Services Task Force (USPSTF) (LeFevre ML et al. Ann Intern Med. doi:10.7326/M14-1018 [publishe...

Harvoni will keep Gilead atop Hepatitis C virus treatment landscape, says GlobalData Analyst

The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company to mai...

GlobalData Analyst: Harvoni Will Keep Gilead Atop Hepatitis C Virus Treatment Landscape

The recent US Food and Drug Administration (FDA) approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company ...

[Comment] QUEST for a cure for hepatitis C virus: the end is in sight

Worldwide, an estimated 170–200 million people have chronic hepatitis C virus (HCV) infection. Successful eradication of HCV has been associated with a reduction in these adverse outcomes. However, less than 50% of people infected with HCV genotype...

Hepatitis C Virus Therapy in the Direct Acting Antiviral Era

It is possible to cure chronic hepatitis C in the vast majority of patients with this infection and often without interferon. This new study gives us an overview of treatment strategies. Current Opinion in Gastroenterology

Antiviral treatment of hepatitis C

Hepatitis C virus (HCV) infection is a substantial health problem worldwide. Most patients infected with HCV remain chronically infected, with an increased risk of cirrhosis and hepatocellular...

FDA approves first combination pill to treat hepatitis C

The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.

New Expensive Treatments for Hepatitis C Infection

Treatment of infection with hepatitis C virus (HCV) has changed substantially in the last 3 years, with new therapies now reaching cure rates (defined by sustained virologic response) higher than 95%. As little as 3 years ago, treatment involved an a...

[Articles] Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Simeprevir once daily with peginterferon alfa 2a and ribavirin shortens therapy in treatment-naive patients with HCV genotype 1 infection without worsening the adverse event profiles associated with peginterferon alfa 2a plus ribavirin.

Virus Infection Supports Organ Acceptance

A question of tolerance: Liver transplants in patients with hepatitis C Chronic hepatitis C virus infections are among the most common reasons for liver transplants. Because existing viruses also infect the new liver, the immune system is highly active there. Despite this, the new organ is not rejected, as scientists from the Helmholtz Zentrum München and the Technische Universität M&uum...

[Articles] Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Addition of simeprevir to either peginterferon alfa 2a or peginterferon alfa 2b plus ribavirin improved SVR in treatment-naive patients with HCV genotype 1 infection, without worsening the known adverse events associated with peginterferon alfa plus ...

Methadone programs can be key in educating, treating Hepatitis C patients

People who inject drugs and are enrolled in a drug treatment program are receptive to education about, and treatment for, hepatitis C virus, according to a study. That finding will be welcome news to health care providers. The paper notes that inject...

Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus

(Lifespan) Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection program, states in a commentary in the July, 2014 Rhode Island Medical Journal special edition, 'RI Defeats Hep C' that eliminating hepatitis C virus i...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks